Gene mutations can vary by type, in terms of affecting a single site, spanning hundreds of base pairs, or their over/under-representation in cancer cells. Collectively, these mutation types include: single nucleotide variants (SNVs), structural variants (SVs), and copy number variants (CNVs). Tumor mutation burden is one measure widely used throughout cancer research but it is often limited to a single dimension, using SNVs only. We derive a sample mutation burden for each mutation type and combine them to define their relative contribution, forming a mutation burden composition (MuBuCo). We applied MuBuCo to multiple myeloma, a well-recognized, genomically heterogeneous blood cancer. Using 70 multiple myeloma cell lines, we first computati...
Advances in sequencing technology have made it routine to determine all coding variation in an indiv...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...
The standard approach to multiple myeloma relies on marrow morphology, serum and urine biochemistry ...
Gene mutations can vary by type, in terms of affecting a single site, spanning hundreds of base pair...
The notion that DNA changes could drive the growth of cancer was first speculated more than a centur...
Background: Most tumors are the result of accumulated genomic alterations in somatic cells. The emer...
The genome of a cancer cell is replete with somatic mutations imprinted by the activities of differe...
Cancer cells accumulate somatic mutations as result of DNA damage, inaccurate repair and other mecha...
Background: The catalog of somatic mutations in a cancer is the aggregate outcome of strength and du...
The Cancer Genome Atlas (TCGA) cancer genomics dataset includes over 10,000 tumor-normal exome pairs...
Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation i...
Cancer is an umbrella terminology that binds hundreds of complex genetic diseases based on a set of ...
Tumours accumulate many somatic mutations in their lifetime. Some of these mutations, drivers, conve...
Somatic mutations promote the transformation of normal cells to cancer. Accurate identification of s...
A cancer genome carries the historic mutagenic activity that has occurred throughout the development...
Advances in sequencing technology have made it routine to determine all coding variation in an indiv...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...
The standard approach to multiple myeloma relies on marrow morphology, serum and urine biochemistry ...
Gene mutations can vary by type, in terms of affecting a single site, spanning hundreds of base pair...
The notion that DNA changes could drive the growth of cancer was first speculated more than a centur...
Background: Most tumors are the result of accumulated genomic alterations in somatic cells. The emer...
The genome of a cancer cell is replete with somatic mutations imprinted by the activities of differe...
Cancer cells accumulate somatic mutations as result of DNA damage, inaccurate repair and other mecha...
Background: The catalog of somatic mutations in a cancer is the aggregate outcome of strength and du...
The Cancer Genome Atlas (TCGA) cancer genomics dataset includes over 10,000 tumor-normal exome pairs...
Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation i...
Cancer is an umbrella terminology that binds hundreds of complex genetic diseases based on a set of ...
Tumours accumulate many somatic mutations in their lifetime. Some of these mutations, drivers, conve...
Somatic mutations promote the transformation of normal cells to cancer. Accurate identification of s...
A cancer genome carries the historic mutagenic activity that has occurred throughout the development...
Advances in sequencing technology have made it routine to determine all coding variation in an indiv...
Tumor mutational burden (TMB) is a promising predictive biomarker for cancer immunotherapy. Patients...
The standard approach to multiple myeloma relies on marrow morphology, serum and urine biochemistry ...